|Articles|January 29, 2015

Pharma 2015: Industry in Flux

Pharma is still a 21st Century growth industry, but investment dynamics no longer favor organic growth. Check out our strategic outlook infographic.

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe

Related Content

Redefining Medical Strategy in Obesity Through Real-World iNSIGHTS

ByLexi Cogswell, PhD,Tom Rotolo, PhD

September 2nd 2026

Pharma Has More Data Than Ever, This Doesn’t Mean It Has Better Intelligence

ByRafaat Rahmani

August 31st 2026

The Full Path of Drug Development, and Why So Few Drugs Make It: Q&A with Dr. Ying Huang

ByMike Hollan,Ying Huang, PhD

August 27th 2026

What Executives and Investors Are Looking for in Pharma Companies

ByMike Hollan,Ying Huang, PhD

August 26th 2026

The Path from Discovery to Global Commercialization

ByMike Hollan,Ying Huang, PhD

August 25th 2026

Pharma 2015: Industry in Flux

Related Content

Redefining Medical Strategy in Obesity Through Real-World iNSIGHTS

Pharma Has More Data Than Ever, This Doesn’t Mean It Has Better Intelligence

The Full Path of Drug Development, and Why So Few Drugs Make It: Q&A with Dr. Ying Huang

What Executives and Investors Are Looking for in Pharma Companies

The Path from Discovery to Global Commercialization

Trending on PharmExec

Novartis, Bristol Myers Pause Autoimmune CAR-T Trials Over Safety Concerns: Report

Ultragenyx Shares Drop Following Failed Phase III Clinical Trial

FDA Approves Zanvastro for Alexander Disease in Pediatrics & Adults

Your Questions Answered: The Biggest Pharma and Biotech Stories This Week

The Limitations of JAK Inhibitors When Treating IBD